Towards optimal use of BiTE® antibody constructs nu maximal exploiting the immune system
Towards optimal use of BiTE® antibody constructs nu maximal exploiting the immune system
The usage of bispecific antibodies is a new strategy to combat cancer. The bispecific antibodies, BiTEs in this project, bring the immune cell and the tumor cell together, which leads to an activation of the immune cell. The idea behind this is that the activated immune cell will kill the tumor cell. This technique is already used for hematologic cancer. In this project we will test how BiTE therapy can also be used for solid tumors.
Summary
The usage of bispecific antibodies is a new strategy to combat cancer. The antibodies bring the immune cell and the tumor cell together, which leads to an activation of the immune cell, which kills the tumor cell. In this project we will test how this therapy can be used for solid tumors.
Technology Readiness Level (TRL)
3 - 3
Time period
60 months
Partners
